Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SN 38 immunoconjugates - Immunomedics

Next Previous
Drug Profile

Research programme: SN 38 immunoconjugates - Immunomedics

Alternative Names: Antibody-SN-38 conjugates; CD74-targeted milatuzumab-SN 38 immunoconjugates; Epratuzumab-SN 38; hA20-SN 38; hL243-SN-38; hLL2-SN 38; hPAM4-SN 38; IMMU-114-SN-38; milatuzumab-CL2A-SN 38; milatuzumab-CL2E-SN 38; Milatuzumab-SN 38

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Camptothecins; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Colorectal cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Solid tumours
  • Discontinued Haematological malignancies

Most Recent Events

  • 28 Dec 2022 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)
  • 28 Dec 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top